Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
Jun 06, 2023
FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults Pfizer Inc. announced that the FDA has authorized ABRYSVO (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory...
Read More...
May 05, 2023
Infections due to respiratory syncytial virus (RSV) have seriously troubled drug makers for decades and the need for a vaccine was on since the 1960s. According to the assessment done by DelveInsight on the latest published “Respiratory Syncytial Virus Epidemiology Report,” it is estimated to affect approximately 5...
Read More...
Apr 21, 2023
Respiratory syncytial virus is estimated to affect approximately 5 million cases this year in the United States and 2.5 million RSV cases in the EU4 countries and the United Kingdom. As per Delveinsight analysis on the latest published “Respiratory Syncytial Virus Epidemiology Report,” the US comprised ~70%, ~27%, ...
Read More...
Jan 31, 2023
FDA Approves Eli Lilly’s Jaypirca for Relapsed Mantle Cell Lymphoma Eli Lilly has received FDA approval for Jaypirca, a non-covalent BTK inhibitor, in relapsed mantle cell lymphoma (MCL) patients who have relapsed after treatment with other drugs in the class. Adult MCL patients who have previously received at l...
Read More...
Jan 03, 2023
Gilead Buys Out Rights to Cancer Therapy from Jounce for USD 67 Million Gilead Sciences must have liked what it saw in a two-year-old collaboration with Jounce Therapeutics for CCR8-targeting cancer immunotherapy because the company has just agreed to own the program fully. The drug in question, GS-1811 (formerl...
Read More...
Dec 27, 2022
FDA Approves Gilead Sciences’ Sunlenca Sunlenca, a Gilead Sciences therapy for people with multidrug-resistant (MDR) HIV infection that only needs to be taken twice a year, has received FDA approval for the second time of asking. Sunlenca, which is based on the HIV capsid inhibitor lenacapavir, is intended to be...
Read More...
Sep 07, 2021
Pfizer’s RSV Vaccine enters in the late-stage of clinical trials As the battle to get an effective Respiratory Syncytial Virus (RSV) vaccine on the market heats up, Pfizer is launching a critical late-stage study of its experimental vaccine against a severe version of a cold virus that may cause pneumonia ...
Read More...
Aug 25, 2021
Pharmaceutical companies play a vital part in our lives and in helping us to live healthier lives. The pharmaceutical industry finds, develops, manufactures, and promotes medicines or pharmaceutical drugs for usage as medications that are administered (or self-administered) to patients in order to cure, vaccinate, ...
Read More...
Apr 26, 2021
Cold can make anyone cheerless and miserable, however, having Sinusitis is another story. Also known as rhinosinusitis, Sinusitis makes a person suffer from a stuffy nose, blocked nasal passages, congestion, throbbing pain in eyes, forehead, and cheeks, exhaustion and excess mucous leading to full-blown cold for we...
Read More...
Mar 15, 2021
An X-linked recessive disorder, Hemophilia occurs predominantly in males with females being the carriers. Patients diagnosed with Hemophilia usually lack one of the two proteins essential for the blood coagulation cascade namely factor VIII (FVIII) and factor IX (FIX). On the basis of the different blood coagulatio...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper